These results establish the validity of targeting nuclear transport to reduce hypercholesterolemia, hypertriglyceridemia, atherosclerosis, and fatty liver in a murine model of LDL receptor deficiency. The gene discussed is LDLR; the disease is hypertriglyceridemia.